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Human blood lymphocytes, pre-treated with very low
(adaptation) concentrations of bleomycin for 48 h and then
exposed to a high (challenge) dose of the same agent or
X-rays, became significantly less sensitive to the induction of
chromosome damage than those which did not receive the
pre-treatment, indicating an induction of 'adaptive repair'
process. This repair process was negated when 3-amino-
benzamide, an inhibitor of poly (ADP) polymerase, was added
to the cultures immediately after the challenge treatment.
The magnitude of negation in the adaptation response was
greater in the case of lymphocytes challenged with X-rays as
compared with those challenged with bleomycin.
Introduction
There is growing evidence for the existence of an adaptive
response in human blood lymphocytes, similar to that found in
Escherichia coli (Samson and Cairns, 1977) and rodent cells
(Samson and Schwartz, 1980). Olivieri etal. (1984) first reported
that prior exposure of human lymphocytes to low levels of
radioactive thymidine (3[H]dThd) led to a significant reduction
in the chromosome damage induced by a subsequent high dose
of X-rays. Shadley and Wolff (1987) also observed that an X-ray
dose, as low as 0.01 Gy, can protect the lymphocytes against
the cytogenetic damage induced by a subsequent exposure to 1.5
Gy X-rays. The radiation dose used for adaptation seemed to
have an effect; so also the time-interval between the adaptation
and challenge doses (Shadley etal., 1987), the dose rate and the
quality of radiation (Wiencke et al., 1987). Sankaranarayanan
et al. (1989) have confirmed the original results of Olivieri et
al. (1984). More recently, Wolff et al. (1988) reported that
human blood lymphocytes adapted to low doses of ionizing
radiation became refractory to chromosome damage, not only
by a high dose of radiation but also by chemical mutagens that
induce similar kinds of lesions in DNA.
Bleomycin (BLM) is an anti-tumour antibiotic drug, widely
used in the treatment of a variety of human malignancies
(Bonadonna et al., 1972). Its action on DNA and chromosomes
has been shown to be similar to that of ionizing radiation (Tamura
et al., 1974; Dresp et al., 1978). These similarities prompted
us to investigate whether or not an adaptation response can be
elicited by BLM in human blood lymphocytes. We observed that
prior exposure of the lymphocytes to low doses of BLM made
them significantly less sensitive to the induction of chromosome
damage by subsequent exposure to a high dose of not only BLM
but also X-rays (Vijayalaxmi and Burkart, 1989). These results
lend further support to the operation of an adaptive repair process
in human lymphocytes which offers resistance and cross-
resistance to chromosome damage by the same or similar DNA
damaging agents.
All these studies point to an inducible resistance to DNA
damage and the possible role of the enzymes involved in the repair
of damaged DNA. The activity of poly (ADP-ribose) polymerase
(Skidmore etal., 1979; Durkacz etal., 1980) has been implicated
in lymphocytes adapted to 3[H]dThd and X-rays (Wiencke et
al., 1986; Shadley et al, 1987). A similar study has been
conducted to examine the role of 3-aminobenzamide (3AB), a
potent inhibitor of poly (ADP-ribose) polymerase, on the
chromosome damage in human blood lymphocytes adapted to
BLM. The results are reported here.
Materials and methods
Heparinized blood samples were obtained from two healthy, non-smoking females,
aged between 25 and 30 years. From each sample, separate cultures were set
up using 1 ml blood in 10 ml RPMI1640 medium containing 15% fetal calf serum,
1 % PHA (Gibco), 1 % glutamine, 10 U/ml penicillin, 10 /ig/ml streptomycin and
kept at 37 °C in 5% carbon dioxide incubator. Four hours later, the adaptation
doses of BLM (Lundbeck, Denmark), freshly prepared in sterile distilled water,
were added to give final concentrations of 0.01 and 0.05 /ig/ml and the cultures
returned to the incubator. At 48 h, the cells were exposed to a challenge dose
of 1.5 jig/ml BLM or 1.5 Gy X-rays (Philips X-ray machine, model MCN 321,
240 kV, 7mA, 1-mm aluminium filter; cultures were kept at a distance of 50 cm
from the radiation source and the dose rate of 1.5 Gy was checked using Farmer
dosemeter 2570). 3AB (Sigma), freshly made up in medium to give a final
concentration of 2 mM, was added immediately after the challenge dose. The
incubation continued for a further period of 6 h. For the last 2 h, the cells were
also treated with 1 /ig/ml colcemid (Gibco). Lymphocytes were collected, treated
with 75 mM potassium chloride for 7 min and then fixed in 3:1 methanol:acetic
acid mixture. Fixed cells were dropped onto clean slides, air-dried and stained
with Giemsa. Coded slides'were examined for chromosome damage. Two-hundred
metaphases were analysed from each culture. Gaps and achromatic lesions less
than the width of a chromatid were not included in the scoring. Very few chromatid
exchanges and dicentric chromosomes were recorded but not included in the
analysis. The data on the incidence of chromatid and isochromatid breaks (observed
versus expected) were subjected to statistical analysis using one-tailed (-test.
Results and discussion
The overall response of the lymphocytes from two blood samples
studied is similar and the pooled data on chromosome (chromatid
+ isochromatid) breaks are given in Table I. As can be seen,
the adaptation doses of 0.01 and 0.05 /ig/ml BLM induces a small
increase (2-5%) in the frequency of chromosome breaks,
whereas the challenge dose of 1.5 /tg/ml BLM alone, given 6 h
before fixing the cells, induces a significant number of
chromosome breaks (65%). In lymphocytes which received both
adaptation and challenge doses of BLM, the incidence of
chromosome breaks is significantly lower than those expected
on the basis of additive effects of two individual treatments. The
reduction observed with the adaptation doses of 0.01 and
0.05 /tg/ml BLM is 61 and 54% respectively. The challenge dose
of 1.5 Gy X-rays alone, given to the lymphocytes 6 h before
fixation, induces 30% chromosome breaks. When the cells
adapted to BLM are subsequently challenged with 1.5 Gy X-rays,
the yield of chromosome breaks is significantly lower than the
sum of the effects induced by two treatments separately. The
reduction observed with the adaptation doses of 0.01 and
0.05 /ig/ml BLM is 59 and 52%, respectively. These data
confirm the results of our previous experiments (Vijayalaxmi and
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Table I.
Adaptive
BLM (jig
Effect of 3AB
treatment
;/ml)
on chromosome
Challenge
treatment
damage in human blood lymphocytes adapted to
Chromatid and isochromatid breaks
in 200 cells
Blood sample 1 Blood sample 2
BLM
Total breaks observed
in 400 cells
Expected Percent decrease
0.01
0.05
0.01
0.01
0.05
0.05
0.01
0.01
0.05
0.05
—
3AB
BLM
X-rays
-
-
BLM
BLM + 3AB
BLM
BLM + 3AB
X-rays
X-rays + 3AB
X-rays
X-rays + 3AB
3
3
124
60
5
10
50
91
55
99
26
53
30
56
1
1
136
66
4
12
53
107
72
111
28
60
39
67
4
4
260
126
9
22
103a
198b
127a
210"
54a
113C
69a
123C
265
265
278
278
131
131
144
144
61
25
54
24
59
14
52
15
The treatment schedule is described in Materials and methods. Expected values are the sum of two individual treatments minus the control. Difference
between observed and expected values:
"P < 0.001; bP < 0.025; cnot significant.
Difference between ± 3AB cultures: P < 0.001.
Burkart, 1989) and are in agreement with other published reports
on the induction of adaptation response in human blood lym-
phocytes.
The data presented in Table I also indicate that the addition
of 3AB alone, 6 h before fixing the lymphocytes, has no effect
on the frequency of chromosome breaks over the control value.
When 3AB is added to the adapted lymphocytes, immediately
after the challenge treatment with 1.5 /ig/ml BLM, the reduction
in the incidence of chromosome damage is 25—24%, as
compared with 61—54% (without 3AB treatment). A similar
difference, with and without 3AB treatment, is also observed in
the case of challenge with 1.5 Gy X-rays: 15 —14% as compared
with 59-52%. These results suggest that the addition of 3AB
negates the adaptation response in human lymphocytes and
support the observations made by Wiencke et al. (1986) and
Shadley et al. (1987). However, the magnitude of reduction in
the adaptation response by 3 AB is greater in the case of challenge
with X-rays as compared with BLM.
Chinese hamster ovary cells treated with BLM have been
shown to synthesize poly (ADP-ribose) in a reaction which is
dose- and time-dependent and the addition of inhibitors like 3AB
inhibited this reaction resulting in increased cell killing (Huet and
Laval, 1985) and chromosome damage (Zwanenburg et al.,
1985). Enhancement of anti-tumour activity of BLM by inhibitors
of poly (ADP-ribose) polymerase has also been demonstrated in
vivo and in vitro (Kawamitsu et al., 1982; Sakamoto et al., 1983).
These reports are interesting in the context of the present study
and implicate that poly (ADP-ribose) polymerase is involved not
only in the repair of BLM-induced DNA damage but also in
negating the adaptation response in human lymphocytes. It would
be interesting to study the effect of 3AB on the rate of poly
(ADP-ribose) synthesis and DNA repair kinetics in BLM-adapted
lymphocytes.
The magnitude of negation in the adaptation response is greater
in the case of challenge with 1.5 Gy X-rays as compared with
1.5 /ig/ml BLM. It may be relevant to refer to the data which
suggest that BLM is inactivated by an enzyme, BLM-hydroxylase
(Umezawa, 1973) and that the therapeutic effects of BLM could
be related to the distribution of BLM-hydroxylase in the tissues
(Ichikawa, 1969; Clinical screening group of EORTC, 1970).
Transplantable tumour cell lines which have higher BLM-
hydroxylase are shown to be comparatively more resistant to
BLM (Yoshioka et al., 1978). Whether the adaptation doses of
BLM stimulate the activity of BLM-hydroxylase, which offers
the cells an increased resistance to BLM challenge dose, and
whether the enzyme also plays a role in negating the adaptation
response is not known. Experiments are in progress along these
lines.
BLM is widely used as a therapeutic agent for a variety of
human cancers; depending upon the fractionation of the doses
employed and the duration of treatment, the possibility of an
adaptation response of the tumour tissues/cells should be carefully
assessed. Recently, Sakamoto et al. (1983) have demonstrated
that daily treatment with various doses of BLM + benzamide,
given to mice with Ehrlich ascites tumours, has increased the
survival of the animals as compared with those mice on treatment
with BLM alone. The usefulness of the administration of
inhibitors of poly (ADP-ribose) polymerase/BLM-hydroxylase
along with BLM in the treatment of human cancers remains to
be elucidated.
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